A human immune disease that would later be classified as an IEI was first defined by Ogden Bruton. In the early 1950s, he examined an 8-year-old boy who had 19 episodes of pneumonia over a period of 4 years. Expecting that individuals with such a history of repeated infections would have high levels of infection-fighting antibodies in their serum, Dr. Bruton was surprised to find that the boy had hypogammaglobulinemia, i.e., his serum lacked detectible levels of circulating antibodies which attack infection-causing microorganisms and virus.[9][10] That same year, Dr. Bruton and colleagues published on two other infection-prone patients who also lacked detectable levels of these serum antibodies[10][11] This particular from of hypogammaglobulinemia, now termed X-linked agammaglobulinemia and characterized as an IEI, occurs in about 1 per 379,000 live births.[12][13] It is also termed Bruton's agammaglobulinemia and the gene that when mutated causes this disease is termed the Bruton's tyrosine kinase, i.e., BKT, gene. The product of this gene, the BTK protein, contributes indirectly to promoting the production of all the antibody subtypes, i.e., IgG, IgA, IgM, and IgE.[14]
Impairments in the immune system's protective actions have been referred to as primary immunodeficiencies (PID), i.e., immune deficiencies that are present at birth and not caused by secondary factors such as other diseases or exposure to genotoxic agents.[15] The PID disorders (see List of primary immunodeficiencies) and its subgroup, the primary immune regulatory disorders (PIRDs; i.e., disorders of immunity characterized as excessive proliferations of lymphocytes and the development of immune responses against one's own normal tissues[16]), are immune disorders similar to those in IEI.[2][17] Finally, inborn errors of metabolism (i.e., IEM) are a group of about 1700 disorders caused by a mutation in any one of about 1500 genes that causes a defect in a pathway that metabolizes proteins, fats, or carbohydrates or that impairs the function of a subcellular organelle. This mutation usually causes a complicated medical condition involving several human organ systems.[18][19] When any one of the disorders in the PID, PIRDs, or IEM classifications is caused by a single gene mutation that disrupts the immune system, it is termed an IEI. Consequently, many IEIs are also termed a PID, PIRDs, and/or IEM.[2][17][18][19]
In 1973, the World Health Organization (WHO) established the Inborn Errors of Immunity Committee for the purpose of classifying and identifying immune defects in humans. The committee focused on rare immune diseases. In the 1990s, the WHO decided to focus on more common diseases, and the committee was taken on by the International Union of Immunological Societies (i.e., IUIS). This relationship was made official in 2008.[20] The number of genes that when mutated to cause specific IEI disorders has steadily rose from less than 10 in the 1980s[21] to the IUIS expert committee's 2022 classification of 485 mutated genes causing these disorders.[22] These numbers are expected to increase further as DNA sequencing using automated methods (e.g., massive parallel sequencing), further studies of less severe immune disorders, and analyses of multiple tissues in individuals that may have carry the dysfunctional gene in some but not their tissues (see mosaicism). Thus, the prevalence of IEIs in 2023 was estimated to be between 1 in 1,000 and 1 in 5,000 individuals but this may be an underestimate: its true prevalence may turn out to be as high as 1 in 500 individuals.[2][23][24]
^ abcdGray PE, David C (June 2023). "Inborn Errors of Immunity and Autoimmune Disease". The Journal of Allergy and Clinical Immunology. In Practice. 11 (6): 1602–1622. doi:10.1016/j.jaip.2023.04.018. PMID37119983.
^Moratti M, Conti F, Giannella M, Ferrari S, Borghesi A (November 2022). "How to: Diagnose inborn errors of intrinsic and innate immunity to viral, bacterial, mycobacterial, and fungal infections". Clinical Microbiology and Infection. 28 (11): 1441–1448. doi:10.1016/j.cmi.2022.07.021. PMID35934195.
^Delavari S, Rasouli SE, Fekrvand S, Chavoshzade Z, Mahdaviani SA, Shirmast P, Sharafian S, Sherkat R, Momen T, Aleyasin S, Ahanchian H, Sadeghi-Shabestari M, Esmaeilzadeh H, Barzamini S, Tarighatmonfared F, Salehi H, Esmaeili M, Marzani Z, Fathi N, Abolnezhadian F, Rad MK, Saeedi-Boroujeni A, Shirkani A, Bagheri Z, Salami F, Shad TM, Marzbali MY, Mojtahedi H, Razavi A, Tavakolinia N, Cheraghi T, Tavakol M, Shafiei A, Behniafard N, Ebrahimi SS, Sepahi N, Ghaneimoghadam A, Rezaei A, Kalantari A, Abolhassani H, Rezaei N (February 2024). "Clinical heterogeneity in families with multiple cases of inborn errors of immunity". Clinical Immunology (Orlando, Fla.). 259: 109896. doi:10.1016/j.clim.2024.109896. PMID38184287.
^Cheng J, Dávila Saldaña BJ, Chandrakasan S, Keller M (September 2024). "Pediatric lymphoproliferative disorders associated with inborn errors of immunity". Clinical Immunology (Orlando, Fla.). 266: 110332. doi:10.1016/j.clim.2024.110332. PMID39069111.
^ abPalva T, Lehtinen T (December 1987). "Pneumococcal antigens and endotoxin in effusions from patients with secretory otitis media". International Journal of Pediatric Otorhinolaryngology. 14 (2–3): 123–8. doi:10.1016/0165-5876(87)90022-x. PMID3436716.
^Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, Rundles CC, Franco JL, Holland SM, Klein C, Morio T, Oksenhendler E, Puel A, Puck J, Seppänen MR, Somech R, Su HC, Sullivan KE, Torgerson TR, Meyts I (October 2022). "The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity". Journal of Clinical Immunology. 42 (7): 1508–1520. doi:10.1007/s10875-022-01352-z. PMID36198931.
^Akalu YT, Bogunovic D (March 2024). "Inborn errors of immunity: an expanding universe of disease and genetic architecture". Nature Reviews. Genetics. 25 (3): 184–195. doi:10.1038/s41576-023-00656-z. PMID37863939.